Showing results (121-130 of 177) with videos related to

Sort By:
Pageof 18
Multiple Sclerosis and Related Disorders|September 10, 2020
Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension studyAaron E Miller, Tomas P Olsson, Jerry S Wolinsky, et al.
Neurology|February 12, 2016
Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO studyPaul O'Connor, Giancarlo Comi, Mark S Freedman, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 19, 2011
Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disabilityStefan D Roosendaal, Kerstin Bendfeldt, Hugo Vrenken, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 16, 2013
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trialPatrick Vermersch, Anna Czlonkowska, Luigi M E Grimaldi, et al.
Human Molecular Genetics|June 11, 2013
Blood RNA profiling in a large cohort of multiple sclerosis patients and healthy controlsDorothee Nickles, Hsuan P Chen, Michael M Li, et al.
Journal of Neuroinflammation|June 17, 2020
Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosisWendy Gilmore, Brett T Lund, Peili Li, et al.
Neurology|February 28, 2020
Detection of subtle gait disturbance and future fall risk in early multiple sclerosisRachel Brandstadter, Oluwasheyi Ayeni, Stephen C Krieger, et al.
The Lancet. Neurology|July 11, 2014
Pathogenesis of multiple sclerosis: insights from molecular and metabolic imagingOlga Ciccarelli, Frederik Barkhof, Benedetta Bodini, et al.
Annals of Neurology|August 29, 2012
Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosisEllen M Mowry, Emmanuelle Waubant, Charles E McCulloch, et al.
Pageof 18